Status:
COMPLETED
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
Lead Sponsor:
EPS Corporation
Conditions:
Liver Metastasis
Colorectal Cancer
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to t...
Detailed Description
The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to t...
Eligibility Criteria
Inclusion
- Patients who registered the ATOM trial and signed informed consent prior to initiation of any trial-specific procedure and treatment.
Exclusion
- None
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT01834014
Start Date
May 1 2013
End Date
March 1 2017
Last Update
August 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
EPS Corporation
Shinjuku-ku, Tokyo, Japan, 162-0814